chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 50.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Interchange of vaccine products, Off label use, SARS-CoV-2 test
Clinical narrative: severe pain in her side, which turned into an almost ruptured appendix; perforated appendix and gangrene in there; severe pain in her side, which turned into an almost ruptured appendix; perforated appendix and gangrene in there; Dose 1: Moderna, Dose 2: Moderna; Dose 3: BNT162B2; Dose 1: Moderna, Dose 2: Moderna; Dose 3: BNT162B2; Dose 1: Moderna, Dose 2: Moderna; Dose 3: BNT162B2; she tested positive for Covid 3 days later; she tested positive for Covid 3 days later; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 50 year-old female patient received bnt162b2 (BNT162B2), administered in arm right, administration date 03Jan2022 14:00 (Lot number: FS1611) at the age of 50 years as dose 3 (booster), single for covid-19 immunisation. The patient's relevant medical history was not reported. There were no concomitant medications. Vaccination history included: Moderna (Dose:1, Lot:04QA21A), administration date: 15Mar2021, when the patient was 49 years old, for COVID-19 Immunization; Moderna (Dose:2, Lot:016B21A), administration date: 15Apr2021, when the patient was 49 years old, for COVID-19 Immunization.  The following information was reported: APPENDIX DISORDER (hospitalization) with onset 14Jan2022, outcome "recovering", described as "severe pain in her side, which turned into an almost ruptured appendix; perforated appendix and gangrene in there"; DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant) all with onset 06Jan2022, outcome "unknown" and all described as "she tested positive for Covid 3 days later"; OFF LABEL USE (non-serious), INTERCHANGE OF VACCINE PRODUCTS (non-serious) all with onset 03Jan2022 14:00, outcome "unknown" and all described as "Dose 1: Moderna, Dose 2: Moderna; Dose 3: BNT162B2". The patient was hospitalized for appendix disorder (start date: 14Jan2022, discharge date: 16Jan2022, hospitalization duration: 2 day(s)).   The event "severe pain in her side, which turned into an almost ruptured appendix; perforated appendix and gangrene in there" was evaluated at the emergency room visit. The patient underwent the following laboratory tests and procedures: sars-cov-2 test: (06Jan2022) positive. Therapeutic measures were taken as a result of appendix disorder. Therapeutic measures were taken with Surgery to remove appendix, IV antibiotic and oral antibiotics post discharge. She recovered a week to a week and half later, but she was a month out and she still had some soreness and was healing. She took vaccine for prevention from Covid-19.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Age: 25.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Eye swelling
Clinical narrative: Woke up with a swollen right eye the morning after the took the 3rd dose for the Pfizer vaccine!; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 25 year-old female patient (not pregnant) received bnt162b2 (BNT162B2), administration date 09Feb2022 (Lot number: FK9895) at the age of 25 years as dose 3 (booster), single for covid-19 immunisation. The patient had no relevant medical history. Concomitant medication(s) included: FLU, administration date 09Feb2022. Vaccination history included: Bnt162b2 (Dose Number: 2, Batch/Lot No: Unknown. Not available/provided to reporter at the time of report completion), administration date: 14Jul2021, when the patient was 24 years old, for COVID-19 immunization; Bnt162b2 (Dose Number: 1, Batch/Lot No: Unknown. Not available/provided to reporter at the time of report completion), administration date: 23Jun2021, when the patient was 24 years old, for COVID-19 immunization. The following information was reported: EYE SWELLING (non-serious) with onset 10Feb2022, outcome "not recovered", described as "Woke up with a swollen right eye the morning after the took the 3rd dose for the Pfizer vaccine!". The event "woke up with a swollen right eye the morning after the took the 3rd dose for the pfizer vaccine!" was evaluated at the physician office visit. Therapeutic measures were taken as a result of eye swelling.  Additional information: No covi-19 infection prior vaccination. The patient was not tested covid-19 post vaccination. No known allergies.   Follow-up attempts are completed. No further information is expected.
Age: 17.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Aggression, Aphasia, Blood test normal, Breath holding, Computerised tomogram normal
Clinical narrative: Involuntary movements; seizures; paralysis; loss of speech; loss of memory; Inappropriate schedule of vaccine administered; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 17 year-old female patient (not pregnant) received bnt162b2 (BNT162B2), administered in arm left, administration date 21Dec2021 10:00 (Lot number: 3303OBD) at the age of 17 years as dose 2, single for covid-19 immunisation. Relevant medical history included: "birth control" (unspecified if ongoing). Concomitant medication(s) included: PROZAC; TRI-LO-SPRINTEC taken for contraception. Vaccination history included: Bnt162b2 (Dose 1, administration time: 04:00 PM, lot number: FA7484, vaccine location: Left arm), administration date: 19Aug2021, when the patient was 17 years old, for Covid-19 immunization. The following information was reported: DYSKINESIA (hospitalization, disability) with onset 25Dec2021 18:00, outcome "not recovered", described as "Involuntary movements"; SEIZURE (hospitalization, disability, medically significant) with onset 25Dec2021 18:00, outcome "not recovered", described as "seizures"; PARALYSIS (hospitalization, disability, medically significant) with onset 25Dec2021 18:00, outcome "not recovered", described as "paralysis"; APHASIA (hospitalization, disability) with onset 25Dec2021 18:00, outcome "not recovered", described as "loss of speech"; AMNESIA (hospitalization, disability) with onset 25Dec2021 18:00, outcome "not recovered", described as "loss of memory"; INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (hospitalization, disability) with onset 25Dec2021 18:00, outcome "unknown", described as "Inappropriate schedule of vaccine administered". The patient was hospitalized for dyskinesia, seizure, paralysis, aphasia, amnesia, inappropriate schedule of product administration (hospitalization duration: 2 day(s)). The events "involuntary movements", "seizures", "paralysis", "loss of speech", "loss of memory" and "inappropriate schedule of vaccine administered" were evaluated at the physician office visit and emergency room visit. The patient underwent the following laboratory tests and procedures: sars-cov-2 test: (09Jan2022) negative, notes: Nasal Swab. Therapeutic measures were not taken as a result of dyskinesia, seizure, paralysis, aphasia, amnesia, inappropriate schedule of product administration.  Clinical course:  Involuntary movements much like seizures, paralysis, loss of speech, loss of memory. Multiple episodes happen daily beginning 4 days after vaccine. Episodes last anywhere from 30 minutes to 5 hours. Facility type vaccine was Doctor's office/urgent care. No other vaccine in four weeks. No Known allergies and Other medical history. No covid prior vaccination. Patient was covid tested post vaccination. Covid test type post vaccination was Nasal Swab. Covid test name post vaccination was PCR.
Age: 17.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Crying, Drooling, Dysarthria, Dyskinesia, Dysstasia
Clinical narrative: Involuntary movements; seizures; paralysis; loss of speech; loss of memory; Inappropriate schedule of vaccine administered; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 17 year-old female patient (not pregnant) received bnt162b2 (BNT162B2), administered in arm left, administration date 21Dec2021 10:00 (Lot number: 3303OBD) at the age of 17 years as dose 2, single for covid-19 immunisation. Relevant medical history included: "birth control" (unspecified if ongoing). Concomitant medication(s) included: PROZAC; TRI-LO-SPRINTEC taken for contraception. Vaccination history included: Bnt162b2 (Dose 1, administration time: 04:00 PM, lot number: FA7484, vaccine location: Left arm), administration date: 19Aug2021, when the patient was 17 years old, for Covid-19 immunization. The following information was reported: DYSKINESIA (hospitalization, disability) with onset 25Dec2021 18:00, outcome "not recovered", described as "Involuntary movements"; SEIZURE (hospitalization, disability, medically significant) with onset 25Dec2021 18:00, outcome "not recovered", described as "seizures"; PARALYSIS (hospitalization, disability, medically significant) with onset 25Dec2021 18:00, outcome "not recovered", described as "paralysis"; APHASIA (hospitalization, disability) with onset 25Dec2021 18:00, outcome "not recovered", described as "loss of speech"; AMNESIA (hospitalization, disability) with onset 25Dec2021 18:00, outcome "not recovered", described as "loss of memory"; INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (hospitalization, disability) with onset 25Dec2021 18:00, outcome "unknown", described as "Inappropriate schedule of vaccine administered". The patient was hospitalized for dyskinesia, seizure, paralysis, aphasia, amnesia, inappropriate schedule of product administration (hospitalization duration: 2 day(s)). The events "involuntary movements", "seizures", "paralysis", "loss of speech", "loss of memory" and "inappropriate schedule of vaccine administered" were evaluated at the physician office visit and emergency room visit. The patient underwent the following laboratory tests and procedures: sars-cov-2 test: (09Jan2022) negative, notes: Nasal Swab. Therapeutic measures were not taken as a result of dyskinesia, seizure, paralysis, aphasia, amnesia, inappropriate schedule of product administration.  Clinical course:  Involuntary movements much like seizures, paralysis, loss of speech, loss of memory. Multiple episodes happen daily beginning 4 days after vaccine. Episodes last anywhere from 30 minutes to 5 hours. Facility type vaccine was Doctor's office/urgent care. No other vaccine in four weeks. No Known allergies and Other medical history. No covid prior vaccination. Patient was covid tested post vaccination. Covid test type post vaccination was Nasal Swab. Covid test name post vaccination was PCR.
Age: 17.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Electroencephalogram normal, Excessive eye blinking, Gait inability, Magnetic resonance imaging head normal, Paralysis
Clinical narrative: Involuntary movements; seizures; paralysis; loss of speech; loss of memory; Inappropriate schedule of vaccine administered; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 17 year-old female patient (not pregnant) received bnt162b2 (BNT162B2), administered in arm left, administration date 21Dec2021 10:00 (Lot number: 3303OBD) at the age of 17 years as dose 2, single for covid-19 immunisation. Relevant medical history included: "birth control" (unspecified if ongoing). Concomitant medication(s) included: PROZAC; TRI-LO-SPRINTEC taken for contraception. Vaccination history included: Bnt162b2 (Dose 1, administration time: 04:00 PM, lot number: FA7484, vaccine location: Left arm), administration date: 19Aug2021, when the patient was 17 years old, for Covid-19 immunization. The following information was reported: DYSKINESIA (hospitalization, disability) with onset 25Dec2021 18:00, outcome "not recovered", described as "Involuntary movements"; SEIZURE (hospitalization, disability, medically significant) with onset 25Dec2021 18:00, outcome "not recovered", described as "seizures"; PARALYSIS (hospitalization, disability, medically significant) with onset 25Dec2021 18:00, outcome "not recovered", described as "paralysis"; APHASIA (hospitalization, disability) with onset 25Dec2021 18:00, outcome "not recovered", described as "loss of speech"; AMNESIA (hospitalization, disability) with onset 25Dec2021 18:00, outcome "not recovered", described as "loss of memory"; INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (hospitalization, disability) with onset 25Dec2021 18:00, outcome "unknown", described as "Inappropriate schedule of vaccine administered". The patient was hospitalized for dyskinesia, seizure, paralysis, aphasia, amnesia, inappropriate schedule of product administration (hospitalization duration: 2 day(s)). The events "involuntary movements", "seizures", "paralysis", "loss of speech", "loss of memory" and "inappropriate schedule of vaccine administered" were evaluated at the physician office visit and emergency room visit. The patient underwent the following laboratory tests and procedures: sars-cov-2 test: (09Jan2022) negative, notes: Nasal Swab. Therapeutic measures were not taken as a result of dyskinesia, seizure, paralysis, aphasia, amnesia, inappropriate schedule of product administration.  Clinical course:  Involuntary movements much like seizures, paralysis, loss of speech, loss of memory. Multiple episodes happen daily beginning 4 days after vaccine. Episodes last anywhere from 30 minutes to 5 hours. Facility type vaccine was Doctor's office/urgent care. No other vaccine in four weeks. No Known allergies and Other medical history. No covid prior vaccination. Patient was covid tested post vaccination. Covid test type post vaccination was Nasal Swab. Covid test name post vaccination was PCR.
Age: 17.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Reduced facial expression, SARS-CoV-2 test negative, Screaming, Seizure, Seizure like phenomena
Clinical narrative: Involuntary movements; seizures; paralysis; loss of speech; loss of memory; Inappropriate schedule of vaccine administered; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 17 year-old female patient (not pregnant) received bnt162b2 (BNT162B2), administered in arm left, administration date 21Dec2021 10:00 (Lot number: 3303OBD) at the age of 17 years as dose 2, single for covid-19 immunisation. Relevant medical history included: "birth control" (unspecified if ongoing). Concomitant medication(s) included: PROZAC; TRI-LO-SPRINTEC taken for contraception. Vaccination history included: Bnt162b2 (Dose 1, administration time: 04:00 PM, lot number: FA7484, vaccine location: Left arm), administration date: 19Aug2021, when the patient was 17 years old, for Covid-19 immunization. The following information was reported: DYSKINESIA (hospitalization, disability) with onset 25Dec2021 18:00, outcome "not recovered", described as "Involuntary movements"; SEIZURE (hospitalization, disability, medically significant) with onset 25Dec2021 18:00, outcome "not recovered", described as "seizures"; PARALYSIS (hospitalization, disability, medically significant) with onset 25Dec2021 18:00, outcome "not recovered", described as "paralysis"; APHASIA (hospitalization, disability) with onset 25Dec2021 18:00, outcome "not recovered", described as "loss of speech"; AMNESIA (hospitalization, disability) with onset 25Dec2021 18:00, outcome "not recovered", described as "loss of memory"; INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (hospitalization, disability) with onset 25Dec2021 18:00, outcome "unknown", described as "Inappropriate schedule of vaccine administered". The patient was hospitalized for dyskinesia, seizure, paralysis, aphasia, amnesia, inappropriate schedule of product administration (hospitalization duration: 2 day(s)). The events "involuntary movements", "seizures", "paralysis", "loss of speech", "loss of memory" and "inappropriate schedule of vaccine administered" were evaluated at the physician office visit and emergency room visit. The patient underwent the following laboratory tests and procedures: sars-cov-2 test: (09Jan2022) negative, notes: Nasal Swab. Therapeutic measures were not taken as a result of dyskinesia, seizure, paralysis, aphasia, amnesia, inappropriate schedule of product administration.  Clinical course:  Involuntary movements much like seizures, paralysis, loss of speech, loss of memory. Multiple episodes happen daily beginning 4 days after vaccine. Episodes last anywhere from 30 minutes to 5 hours. Facility type vaccine was Doctor's office/urgent care. No other vaccine in four weeks. No Known allergies and Other medical history. No covid prior vaccination. Patient was covid tested post vaccination. Covid test type post vaccination was Nasal Swab. Covid test name post vaccination was PCR.
Age: 17.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Speech disorder, Tongue biting
Clinical narrative: Involuntary movements; seizures; paralysis; loss of speech; loss of memory; Inappropriate schedule of vaccine administered; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 17 year-old female patient (not pregnant) received bnt162b2 (BNT162B2), administered in arm left, administration date 21Dec2021 10:00 (Lot number: 3303OBD) at the age of 17 years as dose 2, single for covid-19 immunisation. Relevant medical history included: "birth control" (unspecified if ongoing). Concomitant medication(s) included: PROZAC; TRI-LO-SPRINTEC taken for contraception. Vaccination history included: Bnt162b2 (Dose 1, administration time: 04:00 PM, lot number: FA7484, vaccine location: Left arm), administration date: 19Aug2021, when the patient was 17 years old, for Covid-19 immunization. The following information was reported: DYSKINESIA (hospitalization, disability) with onset 25Dec2021 18:00, outcome "not recovered", described as "Involuntary movements"; SEIZURE (hospitalization, disability, medically significant) with onset 25Dec2021 18:00, outcome "not recovered", described as "seizures"; PARALYSIS (hospitalization, disability, medically significant) with onset 25Dec2021 18:00, outcome "not recovered", described as "paralysis"; APHASIA (hospitalization, disability) with onset 25Dec2021 18:00, outcome "not recovered", described as "loss of speech"; AMNESIA (hospitalization, disability) with onset 25Dec2021 18:00, outcome "not recovered", described as "loss of memory"; INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (hospitalization, disability) with onset 25Dec2021 18:00, outcome "unknown", described as "Inappropriate schedule of vaccine administered". The patient was hospitalized for dyskinesia, seizure, paralysis, aphasia, amnesia, inappropriate schedule of product administration (hospitalization duration: 2 day(s)). The events "involuntary movements", "seizures", "paralysis", "loss of speech", "loss of memory" and "inappropriate schedule of vaccine administered" were evaluated at the physician office visit and emergency room visit. The patient underwent the following laboratory tests and procedures: sars-cov-2 test: (09Jan2022) negative, notes: Nasal Swab. Therapeutic measures were not taken as a result of dyskinesia, seizure, paralysis, aphasia, amnesia, inappropriate schedule of product administration.  Clinical course:  Involuntary movements much like seizures, paralysis, loss of speech, loss of memory. Multiple episodes happen daily beginning 4 days after vaccine. Episodes last anywhere from 30 minutes to 5 hours. Facility type vaccine was Doctor's office/urgent care. No other vaccine in four weeks. No Known allergies and Other medical history. No covid prior vaccination. Patient was covid tested post vaccination. Covid test type post vaccination was Nasal Swab. Covid test name post vaccination was PCR.
Age: 17.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Amnesia, Aphasia, Dyskinesia, Inappropriate schedule of product administration, Paralysis
Clinical narrative: Involuntary movements; seizures; paralysis; loss of speech; loss of memory; Inappropriate schedule of vaccine administered; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 17 year-old female patient (not pregnant) received bnt162b2 (BNT162B2), administered in arm left, administration date 21Dec2021 10:00 (Lot number: 3303OBD) at the age of 17 years as dose 2, single for covid-19 immunisation. Relevant medical history included: "birth control" (unspecified if ongoing). Concomitant medication(s) included: PROZAC; TRI-LO-SPRINTEC taken for contraception. Vaccination history included: Bnt162b2 (Dose 1, administration time: 04:00 PM, lot number: FA7484, vaccine location: Left arm), administration date: 19Aug2021, when the patient was 17 years old, for Covid-19 immunization. The following information was reported: DYSKINESIA (hospitalization, disability) with onset 25Dec2021 18:00, outcome "not recovered", described as "Involuntary movements"; SEIZURE (hospitalization, disability, medically significant) with onset 25Dec2021 18:00, outcome "not recovered", described as "seizures"; PARALYSIS (hospitalization, disability, medically significant) with onset 25Dec2021 18:00, outcome "not recovered", described as "paralysis"; APHASIA (hospitalization, disability) with onset 25Dec2021 18:00, outcome "not recovered", described as "loss of speech"; AMNESIA (hospitalization, disability) with onset 25Dec2021 18:00, outcome "not recovered", described as "loss of memory"; INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (hospitalization, disability) with onset 25Dec2021 18:00, outcome "unknown", described as "Inappropriate schedule of vaccine administered". The patient was hospitalized for dyskinesia, seizure, paralysis, aphasia, amnesia, inappropriate schedule of product administration (hospitalization duration: 2 day(s)). The events "involuntary movements", "seizures", "paralysis", "loss of speech", "loss of memory" and "inappropriate schedule of vaccine administered" were evaluated at the physician office visit and emergency room visit. The patient underwent the following laboratory tests and procedures: sars-cov-2 test: (09Jan2022) negative, notes: Nasal Swab. Therapeutic measures were not taken as a result of dyskinesia, seizure, paralysis, aphasia, amnesia, inappropriate schedule of product administration.  Clinical course:  Involuntary movements much like seizures, paralysis, loss of speech, loss of memory. Multiple episodes happen daily beginning 4 days after vaccine. Episodes last anywhere from 30 minutes to 5 hours. Facility type vaccine was Doctor's office/urgent care. No other vaccine in four weeks. No Known allergies and Other medical history. No covid prior vaccination. Patient was covid tested post vaccination. Covid test type post vaccination was Nasal Swab. Covid test name post vaccination was PCR.
Age: 17.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: SARS-CoV-2 test, Seizure
Clinical narrative: Involuntary movements; seizures; paralysis; loss of speech; loss of memory; Inappropriate schedule of vaccine administered; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 17 year-old female patient (not pregnant) received bnt162b2 (BNT162B2), administered in arm left, administration date 21Dec2021 10:00 (Lot number: 3303OBD) at the age of 17 years as dose 2, single for covid-19 immunisation. Relevant medical history included: "birth control" (unspecified if ongoing). Concomitant medication(s) included: PROZAC; TRI-LO-SPRINTEC taken for contraception. Vaccination history included: Bnt162b2 (Dose 1, administration time: 04:00 PM, lot number: FA7484, vaccine location: Left arm), administration date: 19Aug2021, when the patient was 17 years old, for Covid-19 immunization. The following information was reported: DYSKINESIA (hospitalization, disability) with onset 25Dec2021 18:00, outcome "not recovered", described as "Involuntary movements"; SEIZURE (hospitalization, disability, medically significant) with onset 25Dec2021 18:00, outcome "not recovered", described as "seizures"; PARALYSIS (hospitalization, disability, medically significant) with onset 25Dec2021 18:00, outcome "not recovered", described as "paralysis"; APHASIA (hospitalization, disability) with onset 25Dec2021 18:00, outcome "not recovered", described as "loss of speech"; AMNESIA (hospitalization, disability) with onset 25Dec2021 18:00, outcome "not recovered", described as "loss of memory"; INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (hospitalization, disability) with onset 25Dec2021 18:00, outcome "unknown", described as "Inappropriate schedule of vaccine administered". The patient was hospitalized for dyskinesia, seizure, paralysis, aphasia, amnesia, inappropriate schedule of product administration (hospitalization duration: 2 day(s)). The events "involuntary movements", "seizures", "paralysis", "loss of speech", "loss of memory" and "inappropriate schedule of vaccine administered" were evaluated at the physician office visit and emergency room visit. The patient underwent the following laboratory tests and procedures: sars-cov-2 test: (09Jan2022) negative, notes: Nasal Swab. Therapeutic measures were not taken as a result of dyskinesia, seizure, paralysis, aphasia, amnesia, inappropriate schedule of product administration.  Clinical course:  Involuntary movements much like seizures, paralysis, loss of speech, loss of memory. Multiple episodes happen daily beginning 4 days after vaccine. Episodes last anywhere from 30 minutes to 5 hours. Facility type vaccine was Doctor's office/urgent care. No other vaccine in four weeks. No Known allergies and Other medical history. No covid prior vaccination. Patient was covid tested post vaccination. Covid test type post vaccination was Nasal Swab. Covid test name post vaccination was PCR.
Sex: M
Vaccine: COVID19, COVID19, COVID19
Symptoms: Antiacetylcholine receptor antibody positive, Dysarthria, Dysphagia, Electromyogram, Eyelid disorder
Clinical narrative: Myasthenia Gravis; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP) from medical information team.  A 82 year-old male patient received bnt162b2 (BNT162B2), administration date 25Aug2021 (Batch/Lot number: unknown) as dose 3  (booster), single for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. Vaccination history included: Bnt162b2 (Dose: 1), for COVID-19 Immunization; Bnt162b2 (Dose: 2), for Covid-19 immunization. The following information was reported: MYASTHENIA GRAVIS (medically significant), outcome "unknown", described as "Myasthenia Gravis".  Clinical course: Reporter also mentioned about a literature regarding a man with age of withheld who just developed Myasthenia" and that it is not known as his provider may not have reported it.   The lot number for bnt162b2 was not provided and will be requested during follow up.; Sender's Comments: Linked Report(s) : US-PFIZER INC-202200266468 similar report from same reporter
Sex: M
Vaccine: COVID19, COVID19, COVID19
Symptoms: Fatigue, Magnetic resonance imaging, Pain, Photophobia
Clinical narrative: Myasthenia Gravis; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP) from medical information team.  A 82 year-old male patient received bnt162b2 (BNT162B2), administration date 25Aug2021 (Batch/Lot number: unknown) as dose 3  (booster), single for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. Vaccination history included: Bnt162b2 (Dose: 1), for COVID-19 Immunization; Bnt162b2 (Dose: 2), for Covid-19 immunization. The following information was reported: MYASTHENIA GRAVIS (medically significant), outcome "unknown", described as "Myasthenia Gravis".  Clinical course: Reporter also mentioned about a literature regarding a man with age of withheld who just developed Myasthenia" and that it is not known as his provider may not have reported it.   The lot number for bnt162b2 was not provided and will be requested during follow up.; Sender's Comments: Linked Report(s) : US-PFIZER INC-202200266468 similar report from same reporter
Sex: M
Vaccine: COVID19, COVID19, COVID19
Symptoms: Myasthenia gravis
Clinical narrative: Myasthenia Gravis; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP) from medical information team.  A 82 year-old male patient received bnt162b2 (BNT162B2), administration date 25Aug2021 (Batch/Lot number: unknown) as dose 3  (booster), single for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. Vaccination history included: Bnt162b2 (Dose: 1), for COVID-19 Immunization; Bnt162b2 (Dose: 2), for Covid-19 immunization. The following information was reported: MYASTHENIA GRAVIS (medically significant), outcome "unknown", described as "Myasthenia Gravis".  Clinical course: Reporter also mentioned about a literature regarding a man with age of withheld who just developed Myasthenia" and that it is not known as his provider may not have reported it.   The lot number for bnt162b2 was not provided and will be requested during follow up.; Sender's Comments: Linked Report(s) : US-PFIZER INC-202200266468 similar report from same reporter
Age: 41.0
Sex: M
Vaccine: COVID19, COVID19, COVID19, COVID19
Symptoms: Pain, Tremor
Clinical narrative: 1 day after receiving the vaccine my pain was back to a 10+ to the point I was shaking from the pain.; 1 day after receiving the vaccine my pain was back to a 10+ to the point I was shaking from the pain.; 1 day after receiving the vaccine my pain was back to a 10+ to the point I was shaking from the pain.; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 41 year-old male patient received bnt162b2 (BNT162B2), administered in arm left, administration date 22Jan2022 (Lot number: 33025BD) at the age of 41 years as dose 3 (booster), single for covid-19 immunisation. Relevant medical history included: "Polycystic kidney disease" (unspecified if ongoing); "Type II diabetes" (unspecified if ongoing). Patient had an underlying disease. The patient's concomitant medications were not reported. Vaccination history included: Bnt162b2 (Dose 2, single, Batch/Lot No: EN6206, Location of injection: Arm Left), administration date: 13Mar2021, when the patient was 40 years old, for Covid-19 immunization, reaction(s): "my kidneys went from being in no pain to a 10/10 on the pain scale 1 week after receiving the vaccine."; Bnt162b2 (Dose1, single, Batch/Lot No: EN6200), administration date: 20Feb2021, when the patient was 40 years old, for Covid-19 immunization, reaction(s): ". I did not have an adverse reaction to the first vaccine". The following information was reported: RENAL PAIN (disability), TREMOR (disability), CONDITION AGGRAVATED (disability) all with onset 23Jan2022, outcome "not recovered" and all described as "1 day after receiving the vaccine my pain was back to a 10+ to the point I was shaking from the pain.". The patient underwent the following laboratory tests and procedures: pain assessment: (23Jan2022) 10+; sars-cov-2 test: (unspecified date) negative. Therapeutic measures were taken as a result of renal pain, tremor, condition aggravated.  Clinical course: One week after receiving second dose of the vaccine his kidneys went from being in no pain to a 10/10 on the pain scale 1 week after receiving the vaccine. This pain dissipated down to a 8/10 after 3 months but never resolved. He was required to get the booster to continue attending school. 1 day after receiving the vaccine his pain was back to a 10+ to the point he was shaking from the pain. This has still not resolved 3 weeks later. Nephrologist stated no treatment available. Patient had no known allergies. The patient didn't receive any other vaccines within 4 weeks prior to the COVID vaccine (prior vaccination was none). Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient has been tested for COVID-19.
Age: 41.0
Sex: M
Vaccine: COVID19, COVID19, COVID19, COVID19
Symptoms: Condition aggravated, Pain assessment, Renal pain, SARS-CoV-2 test, Tremor
Clinical narrative: 1 day after receiving the vaccine my pain was back to a 10+ to the point I was shaking from the pain.; 1 day after receiving the vaccine my pain was back to a 10+ to the point I was shaking from the pain.; 1 day after receiving the vaccine my pain was back to a 10+ to the point I was shaking from the pain.; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 41 year-old male patient received bnt162b2 (BNT162B2), administered in arm left, administration date 22Jan2022 (Lot number: 33025BD) at the age of 41 years as dose 3 (booster), single for covid-19 immunisation. Relevant medical history included: "Polycystic kidney disease" (unspecified if ongoing); "Type II diabetes" (unspecified if ongoing). Patient had an underlying disease. The patient's concomitant medications were not reported. Vaccination history included: Bnt162b2 (Dose 2, single, Batch/Lot No: EN6206, Location of injection: Arm Left), administration date: 13Mar2021, when the patient was 40 years old, for Covid-19 immunization, reaction(s): "my kidneys went from being in no pain to a 10/10 on the pain scale 1 week after receiving the vaccine."; Bnt162b2 (Dose1, single, Batch/Lot No: EN6200), administration date: 20Feb2021, when the patient was 40 years old, for Covid-19 immunization, reaction(s): ". I did not have an adverse reaction to the first vaccine". The following information was reported: RENAL PAIN (disability), TREMOR (disability), CONDITION AGGRAVATED (disability) all with onset 23Jan2022, outcome "not recovered" and all described as "1 day after receiving the vaccine my pain was back to a 10+ to the point I was shaking from the pain.". The patient underwent the following laboratory tests and procedures: pain assessment: (23Jan2022) 10+; sars-cov-2 test: (unspecified date) negative. Therapeutic measures were taken as a result of renal pain, tremor, condition aggravated.  Clinical course: One week after receiving second dose of the vaccine his kidneys went from being in no pain to a 10/10 on the pain scale 1 week after receiving the vaccine. This pain dissipated down to a 8/10 after 3 months but never resolved. He was required to get the booster to continue attending school. 1 day after receiving the vaccine his pain was back to a 10+ to the point he was shaking from the pain. This has still not resolved 3 weeks later. Nephrologist stated no treatment available. Patient had no known allergies. The patient didn't receive any other vaccines within 4 weeks prior to the COVID vaccine (prior vaccination was none). Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient has been tested for COVID-19.
Age: 78.0
Sex: F
Vaccine: COVID19, COVID19, COVID19, COVID19
Symptoms: Alopecia, Full blood count, Laboratory test, Platelet count increased
Clinical narrative: labs performed: Platelet=591, only out of range result.; Sudden unexplained extreme hair loss/Hair continues falling out daily and 2 weeks later, 3/4 of my hair is gone.; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 78 year-old female patient (not pregnant) received bnt162b2 (BNT162B2), administered in arm left, administration date 02Nov2021 (Lot number: FF2590) at the age of 78 years as dose 3 (booster), single for covid-19 immunisation. Relevant medical history included: "recurrent bladder cancer" (unspecified if ongoing). Concomitant medication(s) included: FLUZONE HIGH DOSE QUADRIVALENT, administration date 13Oct2021; AMLODIPINE; LOSARTAN; CELEBREX; CLONAZEPAM; METOPROLOL. Past drug history included: Msg, reaction(s): "known allergies: MSG". Vaccination history included: Bnt162b2 (Prev dose product: COVID 19, Prev dose brand: Pfizer, Prev dose brand unknown: False, Prev dose lot number: EM9810, Prev dose lot unknown: False, Prev dose administration date: 09Feb2021 , Prev dose dose number: 2, Prev dose vaccine location=Left arm), administration date: 09Feb2021, when the patient was 77 years old, for covid-19 immunization; Bnt162b2 (Prev dose product: COVID 19, Prev dose brand: Pfizer, Prev dose brand unknown: False, Prev dose lot number: EL3249, Prev dose lot unknown: False , Prev dose administration date=19Jan2021, Prev dose dose number: 1, Prev dose vaccine location: Left arm), administration date: 19Jan2021, when the patient was 77 years old, for covid-19 immunization. The following information was reported: PLATELET DISORDER (medically significant) with onset 30Jan2022, outcome "not recovered", described as "labs performed: Platelet=591, only out of range result."; ALOPECIA (non-serious) with onset 30Jan2022, outcome "not recovered", described as "Sudden unexplained extreme hair loss/Hair continues falling out daily and 2 weeks later, 3/4 of my hair is gone.". The events "labs performed: platelet=591, only out of range result." and "sudden unexplained extreme hair loss/hair continues falling out daily and 2 weeks later, 3/4 of my hair is gone." were evaluated at the physician office visit. The patient underwent the following laboratory tests and procedures: platelet count: (30Jan2022) platelet=591, notes: Platelet=591 only out of range result; sars-cov-2 test: (14Jan2022) negative. Therapeutic measures were not taken as a result of platelet disorder, alopecia.  Clinical information: Other vaccine 4 weeks lot number: NDC: 49281-0121-65. Sudden unexplained extreme hair loss. Consulted doctor, labs performed: Platelet: 591, only out of range result. Hair continues falling out daily and 2 weeks later, 3/4 of my hair is gone. No covid prior vaccination. Covid tested post vaccination.  No follow up attempts are possible. No further information is expected.
Age: 78.0
Sex: F
Vaccine: COVID19, COVID19, COVID19, COVID19
Symptoms: Alopecia, Platelet count, Platelet disorder, SARS-CoV-2 test
Clinical narrative: labs performed: Platelet=591, only out of range result.; Sudden unexplained extreme hair loss/Hair continues falling out daily and 2 weeks later, 3/4 of my hair is gone.; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 78 year-old female patient (not pregnant) received bnt162b2 (BNT162B2), administered in arm left, administration date 02Nov2021 (Lot number: FF2590) at the age of 78 years as dose 3 (booster), single for covid-19 immunisation. Relevant medical history included: "recurrent bladder cancer" (unspecified if ongoing). Concomitant medication(s) included: FLUZONE HIGH DOSE QUADRIVALENT, administration date 13Oct2021; AMLODIPINE; LOSARTAN; CELEBREX; CLONAZEPAM; METOPROLOL. Past drug history included: Msg, reaction(s): "known allergies: MSG". Vaccination history included: Bnt162b2 (Prev dose product: COVID 19, Prev dose brand: Pfizer, Prev dose brand unknown: False, Prev dose lot number: EM9810, Prev dose lot unknown: False, Prev dose administration date: 09Feb2021 , Prev dose dose number: 2, Prev dose vaccine location=Left arm), administration date: 09Feb2021, when the patient was 77 years old, for covid-19 immunization; Bnt162b2 (Prev dose product: COVID 19, Prev dose brand: Pfizer, Prev dose brand unknown: False, Prev dose lot number: EL3249, Prev dose lot unknown: False , Prev dose administration date=19Jan2021, Prev dose dose number: 1, Prev dose vaccine location: Left arm), administration date: 19Jan2021, when the patient was 77 years old, for covid-19 immunization. The following information was reported: PLATELET DISORDER (medically significant) with onset 30Jan2022, outcome "not recovered", described as "labs performed: Platelet=591, only out of range result."; ALOPECIA (non-serious) with onset 30Jan2022, outcome "not recovered", described as "Sudden unexplained extreme hair loss/Hair continues falling out daily and 2 weeks later, 3/4 of my hair is gone.". The events "labs performed: platelet=591, only out of range result." and "sudden unexplained extreme hair loss/hair continues falling out daily and 2 weeks later, 3/4 of my hair is gone." were evaluated at the physician office visit. The patient underwent the following laboratory tests and procedures: platelet count: (30Jan2022) platelet=591, notes: Platelet=591 only out of range result; sars-cov-2 test: (14Jan2022) negative. Therapeutic measures were not taken as a result of platelet disorder, alopecia.  Clinical information: Other vaccine 4 weeks lot number: NDC: 49281-0121-65. Sudden unexplained extreme hair loss. Consulted doctor, labs performed: Platelet: 591, only out of range result. Hair continues falling out daily and 2 weeks later, 3/4 of my hair is gone. No covid prior vaccination. Covid tested post vaccination.  No follow up attempts are possible. No further information is expected.
Sex: M
Vaccine: UNK, COVID19
Symptoms: Magnetic resonance imaging normal, Viral infection
Clinical narrative: Tinnitus in my ear; hearing loss; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 46 year-old male patient received bnt162b2 (BNT162B2) (Batch/Lot number: unknown) as dose 2, single for covid-19 immunisation. The patient had no relevant medical history. There were no concomitant medications. Vaccination history included: Covid19 vaccine (Pre dose Number: 1, Prev dose lot unknown=True, prev dose lot unknown reason=Not available/provided to reporter at the time of report completion,), for COVID-19 immunization. The following information was reported: TINNITUS (disability) with onset 01Sep2021, outcome "not recovered", described as "Tinnitus in my ear"; DEAFNESS (disability) with onset 01Sep2021, outcome "not recovered", described as "hearing loss". The events "tinnitus in my ear" and "hearing loss" were evaluated at the physician office visit. The patient underwent the following laboratory tests and procedures: magnetic resonance imaging: unknown result, notes: AE treatment Ear drops and MRI. Therapeutic measures were taken as a result of tinnitus, deafness.  Addition information: It was reported that: told by the Doctor the hearing loss in permanent. Other vaccine in Four weeks was none. Known allergy was none. Covid prior vaccination was none. Covid tested post vaccination was none.  The lot number for bnt162b2 was not provided and will be requested during follow up.
Sex: M
Vaccine: UNK, COVID19
Symptoms: Deafness, Magnetic resonance imaging, Tinnitus
Clinical narrative: Tinnitus in my ear; hearing loss; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 46 year-old male patient received bnt162b2 (BNT162B2) (Batch/Lot number: unknown) as dose 2, single for covid-19 immunisation. The patient had no relevant medical history. There were no concomitant medications. Vaccination history included: Covid19 vaccine (Pre dose Number: 1, Prev dose lot unknown=True, prev dose lot unknown reason=Not available/provided to reporter at the time of report completion,), for COVID-19 immunization. The following information was reported: TINNITUS (disability) with onset 01Sep2021, outcome "not recovered", described as "Tinnitus in my ear"; DEAFNESS (disability) with onset 01Sep2021, outcome "not recovered", described as "hearing loss". The events "tinnitus in my ear" and "hearing loss" were evaluated at the physician office visit. The patient underwent the following laboratory tests and procedures: magnetic resonance imaging: unknown result, notes: AE treatment Ear drops and MRI. Therapeutic measures were taken as a result of tinnitus, deafness.  Addition information: It was reported that: told by the Doctor the hearing loss in permanent. Other vaccine in Four weeks was none. Known allergy was none. Covid prior vaccination was none. Covid tested post vaccination was none.  The lot number for bnt162b2 was not provided and will be requested during follow up.
Age: 53.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Contusion, Injection site erythema, Injection site nodule, Injection site pain, Injection site reaction
Clinical narrative: Pain from injection site to the neck and through the shoulder; Pain from injection site to the neck and through the shoulder; This is a spontaneous report received from a contactable reporter (other healthcare professional). The reporter is the patient.  A 53-year-old female patient (not pregnant) received bnt162b2 (BNT162B2), administered in left arm, administration date 09Feb2022 at 15:15 (Lot number: FJ6369) at the age of 53 years as dose 3 (tris booster), single for COVID-19 immunisation. Relevant medical history included: "COVID-19" (unspecified if ongoing), notes: Prior to vaccination, was the patient diagnosed with COVID-19?: Yes. The patient did not receive any concomitant medications. Vaccination history included: Bnt162b2 (DOSE 1, SINGLE; Lot Number: EJ1685; Anatomical Location: Left arm; Administration time: 06:00), administration date: 18Dec2020, when the patient was 52 years old, for COVID-19 immunisation and Bnt162b2 (DOSE 2, SINGLE; Lot Number: EJ1686; Anatomical Location: Right arm; Administration time: 06:00), administration date: 08Jan2021, when the patient was 52 years old, for COVID-19 immunisation.  The following information was reported: VACCINATION SITE PAIN (non-serious); PAIN (non-serious); all with onset 10Feb2022, outcome "not recovered", and all described as "Pain from injection site to the neck and through the shoulder". Therapeutic measures were not taken as a result of vaccination site pain and pain.  Additional information: It was unknown if the patient had any known allergies. Prior to the vaccination, the patient was diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. Since the vaccination, the patient had not been tested for COVID-19. The events did not result in doctor or other healthcare professional office/clinic visit and emergency room/department or urgent care.
Age: 53.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Injection site swelling, Musculoskeletal stiffness, Pain, Pain in extremity
Clinical narrative: Pain from injection site to the neck and through the shoulder; Pain from injection site to the neck and through the shoulder; This is a spontaneous report received from a contactable reporter (other healthcare professional). The reporter is the patient.  A 53-year-old female patient (not pregnant) received bnt162b2 (BNT162B2), administered in left arm, administration date 09Feb2022 at 15:15 (Lot number: FJ6369) at the age of 53 years as dose 3 (tris booster), single for COVID-19 immunisation. Relevant medical history included: "COVID-19" (unspecified if ongoing), notes: Prior to vaccination, was the patient diagnosed with COVID-19?: Yes. The patient did not receive any concomitant medications. Vaccination history included: Bnt162b2 (DOSE 1, SINGLE; Lot Number: EJ1685; Anatomical Location: Left arm; Administration time: 06:00), administration date: 18Dec2020, when the patient was 52 years old, for COVID-19 immunisation and Bnt162b2 (DOSE 2, SINGLE; Lot Number: EJ1686; Anatomical Location: Right arm; Administration time: 06:00), administration date: 08Jan2021, when the patient was 52 years old, for COVID-19 immunisation.  The following information was reported: VACCINATION SITE PAIN (non-serious); PAIN (non-serious); all with onset 10Feb2022, outcome "not recovered", and all described as "Pain from injection site to the neck and through the shoulder". Therapeutic measures were not taken as a result of vaccination site pain and pain.  Additional information: It was unknown if the patient had any known allergies. Prior to the vaccination, the patient was diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. Since the vaccination, the patient had not been tested for COVID-19. The events did not result in doctor or other healthcare professional office/clinic visit and emergency room/department or urgent care.